Needham & Company analyst Alan Carr reiterated a Buy rating and $23 price target on Cara Therapeutics (NASDAQ: CARA) after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE